Search

Your search keyword '"Ciardiello, D."' showing total 276 results
Start Over Author "Ciardiello, D."
276 results on '"Ciardiello, D."'

1. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial

Author

Ciardiello, Davide, Bielo, Luca Boscolo, Napolitano, Stefania, Martinelli, Erika, Troiani, Teresa, Nicastro, Antonella, Latiano, Tiziana Pia, Parente, Paola, Maiello, Evaristo, Avallone, Antonio, Normanno, Nicola, Pisconti, Salvatore, Nisi, Claudia, Bordonaro, Roberto, Russo, Alessia Erika, Tamburrini, Emiliano, Toma, Ilaria, Lotesoriere, Claudio, Vallarelli, Simona, Zampino, Maria Giulia, Fazio, Nicola, Curigliano, Giuseppe, Ciardiello, Fortunato, Martini, Giulia, Lonardi, Sara, Cremolini, Chiara, Garufi, Carlo, Tagliaferri, Pierosandro, Tortora, Giampaolo, Pietrantonio, Filippo, Febbraro, Antonio, Rosati, Gerardo, Leo, Silvana, Brunetti, Oronzo, Berardi, Rosanna, Cinieri, Saverio, Scartozzi, Mario, Zaniboni, Alberto, Paoletti, Giancarlo, Ciardiello, D., Boscolo Bielo, L., Napolitano, S., Martinelli, E., Troiani, T., Nicastro, A., Latiano, T.P., Parente, P., Maiello, E., Avallone, A., Normanno, N., Pisconti, S., Nisi, C., Bordonaro, R., Russo, A.E., Tamburini, E., Toma, I., Lotesoriere, C., Vallarelli, S., Zampino, M.G., Fazio, N., Curigliano, G., De Vita, F., Ciardiello, F., and Martini, G.

Published
2024
Full Text
View/download PDF

5. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer

Author

Martini, G., Belli, V., Napolitano, S., Ciaramella, V., Ciardiello, D., Belli, A., Izzo, F., Avallone, A., Selvaggi, F., Menegon Tasselli, F., Santaniello, W., Franco, R., Puig, I., Ramirez, L., Chicote, I., Mancuso, F., Caratu, G., Serres, X., Fasani, R., Jimenez, J., Ros, J., Baraibar, I., Mulet, N., Della Corte, C.M., Troiani, T., Vivancos, A., Dienstmann, R., Elez, E., Palmer, H.G., Tabernero, J., Martinelli, E., Ciardiello, F., and Argilés, G.

Published
2023
Full Text
View/download PDF

7. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)

Author

Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M.G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., Rapisardi, S., Bordonaro, R., Zichi, C., De Vita, F., Di Maio, M., Parisi, A., Giampieri, R., Berardi, R., Lavacchi, D., Antonuzzo, L., Tamburini, E., Maiorano, B.A., Parrella, P., Latiano, T.P., Normanno, N., De Stefano, A., Avallone, A., Martini, G., Napolitano, S., Troiani, T., Martinelli, E., Ciardiello, F., and Maiello, E.

Published
2022
Full Text
View/download PDF

11. Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, Martinelli, E, Martini, G, Ciardiello, D, Famiglietti, V, Rossini, D, Antoniotti, C, Troiani, T, Napolitano, S, Esposito, L, Latiano, T P, Maiello, E, Del Re, M, Lonardi, S, Aprile, G, Santini, D, Masi, G, Avallone, A, Normanno, N, Pietrantonio, F, Pinto, C, Ciardiello, F, Cremolini, C, and Martinelli, E

Subjects
metastatic colorectal cancer, cetuximab, rechallenge, immunotherapy
Abstract

The rechallenge strategy is based on the concept that a subset of patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) could still benefit of epidermal growth factor receptor (EGFR) inhibition, after progression to an anti-EGFR based-therapy. We performed a pooled analysis of two-phase II prospective trials to determine the role of rechallenge in third-line mCRC patients with RAS/BRAF WT baseline circulating tumor DNA (ctDNA). Individual data of 33 and 13 patients from CAVE and CRICKET trials that received as third-line therapy cetuximab rechallenge were collected. Overall survival (OS), Progression-free survival (PFS), Overall response rate (ORR), Stable disease (SD) > 6 months were calculated. Adverse events were reported. For the whole 46 patient population, median PFS (mPFS) was 3.9 months (95% Confidence Interval, CI 3.0-4.9) with median OS (mOS) of 16.9 months (95% CI 11.7-22.1). For CRICKET patients, mPFS was 3.9 months (95% CI 1.7-6.2); mOS was 13.1 months (95% CI 7.3-18.9) with OS rates at 12, 18, and 24 months of 62%, 23%, and 0%, respectively. For CAVE patients, mPFS was 4.1 months (95% CI 3.0-5.2); mOS was 18.6 months (95% CI 11.7-25.4) with OS rates at 12, 18, 24 months of 61%, 52%, 21%, respectively. Skin rash was more frequently reported in CAVE trial (87.9% vs. 30.8%; p = 0.001), whereas a increased incidence of hematological toxicities was observed in CRICKET trial (53.8%% vs. 12.1%; p = 0.003). Third-line cetuximab rechallenge in combination with either irinotecan or avelumab in RAS/BRAF WT ctDNA mCRC patients represents a promising therapy.

Published
2023

13. Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA : Individual patient data pooled analysis of CRICKET and CAVE trials

Author

Martini, G., primary, Ciardiello, D., additional, Famiglietti, V., additional, Rossini, D., additional, Antoniotti, C., additional, Troiani, T., additional, Napolitano, S., additional, Esposito, L., additional, Latiano, T. P., additional, Maiello, E., additional, Del Re, M., additional, Lonardi, S., additional, Aprile, G., additional, Santini, D., additional, Masi, G., additional, Avallone, A., additional, Normanno, N., additional, Pietrantonio, F., additional, Pinto, C., additional, Ciardiello, F., additional, Cremolini, C., additional, and Martinelli, E., additional

Published
2023
Full Text
View/download PDF

15. Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)

Author

Ciardiello, D, Chiarazzo, C, Famiglietti, V, Damato, A, Pinto, C, Zampino, M G, Castellano, G, Gervaso, L, Zaniboni, A, Oneda, E, Rapisardi, S, Bordonaro, R, Zichi, C, De Vita, F, Di Maio, M, Parisi, A, Giampieri, R, Berardi, R, Lavacchi, D, Antonuzzo, L, Tamburini, E, Maiorano, B A, Parrella, P, Latiano, T P, Normanno, N, De Stefano, A, Avallone, A, Martini, G, Napolitano, S, Troiani, T, Martinelli, E, Ciardiello, F, Maiello, E, Ciardiello, D, Chiarazzo, C, Famiglietti, V, Damato, A, Pinto, C, Zampino, M G, Castellano, G, Gervaso, L, Zaniboni, A, Oneda, E, Rapisardi, S, Bordonaro, R, Zichi, C, De Vita, F, Di Maio, M, Parisi, A, Giampieri, R, Berardi, R, Lavacchi, D, Antonuzzo, L, Tamburini, E, Maiorano, B A, Parrella, P, Latiano, T P, Normanno, N, De Stefano, A, Avallone, A, Martini, G, Napolitano, S, Troiani, T, Martinelli, E, Ciardiello, F, and Maiello, E

Subjects
KRASG12C mutation, Cancer Research, real-world data, Irinotecan, chemotherapy, first line treatment, Oxaliplatin, Treatment Outcome, Oncology, mCRC, Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Fluorouracil, Colorectal Neoplasms, Retrospective Studies
Abstract

Background: The presence of KRASG12C mutation in metastatic colorectal cancer (mCRC) correlates with poor outcome. Although different selective inhibitors are under clinical development, the optimal treatment remains uncertain. Thus, we conducted a retrospective analysis in a large cohort of patients with KRASG12C mCRC treated in 12 Italian oncology units. Patients and methods: Patients with unresectable mCRC harboring KRASG12C mutation receiving a first-line chemotherapy doublet or triplet between 2011 and 2021 were included in the study. Evaluation of overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) analysis was carried out. Results: A total of 256/6952 (3.7%) patients with mCRC displayed KRASG12C mutation; of these, 111 met the inclusion criteria. The ORR of first-line therapy was 38.7% (43/111). Median PFS (mPFS) was 9 months [95% confidence interval (CI) 7.5-10.5 months]. After progression, only 62% and 36% of the patients are fit to receive second or third lines of treatment, with limited clinical benefit. Median OS (mOS) was 21 months (95% CI 17.4-24.6 months). In patients receiving first-line triplet chemotherapy, ORR was 56.3% (9/16), mPFS was 13 months (95% CI 10.3-15.7 months) and mOS was 32 months (95% CI 7.7-56.3 months). For irinotecan-based doublets, ORR was 34.5 (10/29), mPFS was 9 months (95% CI 6.4-11.6 months) and mOS was 22 months (95% CI 16.0-28.0 months). With oxaliplatin-based doublets ORR was 36.4% (24/62), mPFS was 7 months (95% CI 4.6-9.4 months) and mOS was 18 months (95% CI, 13.6-22.4 months). Conclusion: Patients with KRASG12C-mutant mCRC had a disappointing response to standard treatments. Within the limitations of a retrospective study, these results suggest that first-line chemotherapy intensification with FOLFOXIRI is a valid option in fit patients.

Published
2022

18. O-7 Evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients: Findings from long-term follow-up of CRICKET and CAVE trials

Author

Martinelli, E., primary, Martini, G., additional, Ciardiello, D., additional, Famiglietti, V., additional, Rossini, D., additional, Antoniotti, C., additional, Troiani, T., additional, Napolitano, S., additional, Esposito, L., additional, Latiano, T., additional, Maiello, E., additional, Del Re, M., additional, Lonardi, S., additional, Aprile, G., additional, Santini, D., additional, Masi, G., additional, Avallone, A., additional, Normanno, N., additional, Pietrantonio, F., additional, Pinto, C., additional, Ciardiello, F., additional, and Cremolini, C., additional

Published
2022
Full Text
View/download PDF

20. 163P Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial

Author

Della Corte, C.M., primary, Fasano, M., additional, Ciaramella, V., additional, Cimmino, F., additional, Cardnell, R., additional, Gay, C.M., additional, Ramkumar, K., additional, Diao, L., additional, Di Liello, R., additional, Viscardi, G., additional, Famiglietti, V., additional, Ciardiello, D., additional, Martini, G., additional, Napolitano, S., additional, Troiani, T., additional, Martinelli, E., additional, Wang, J., additional, Byers, L., additional, Morgillo, F., additional, and Ciardiello, F., additional

Published
2022
Full Text
View/download PDF

21. Clinical management of metastatic colorectal cancer in the era of precision medicine

Author

Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, and Cervantes A

Subjects
molecular target therapy, metastatic colorectal cancer, precision medicine, immunotherapy, tumor molecular profiling
Abstract

Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second most common cause of cancer deaths. Initial clinical presentation as metastatic CRC (mCRC) occurs in approximately 20% of patients. Moreover, up to 50% of patients with localized disease eventually develop metastases. Appropriate clinical management of these patients is still a challenging medical issue. Major efforts have been made to unveil the molecular landscape of mCRC. This has resulted in the identification of several druggable tumor molecular targets with the aim of developing personalized treatments for each patient. This review summarizes the improvements in the clinical management of patients with mCRC in the emerging era of precision medicine. In fact, molecular stratification, on which the current treatment algorithm for mCRC is based, although it does not completely represent the complexity of this disease, has been the first significant step toward clinically informative genetic profiling for implementing more effective therapeutic approaches. This has resulted in a clinically relevant increase in mCRC disease control and patient survival. The next steps in the clinical management of mCRC will be to integrate the comprehensive knowledge of tumor gene alterations, of tumor and microenvironment gene and protein expression profiling, of host immune competence as well as the application of the resulting dynamic changes to a precision medicine-based continuum of care for each patient. This approach could result in the identification of individual prognostic and predictive parameters, which could help the clinician in choosing the most appropriate therapeutic program(s) throughout the entire disease journey for each patient with mCRC. CA Cancer J Clin. 2022;72:000-000.

Published
2022

23. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer

Author

Cardone C., Blauensteiner B., Moreno-Viedma V., Martini G., Simeon V., Vitiello P. P., Ciardiello D., Belli V., Matrone N., Troiani T., Morgillo F., Zito Marino F., Dentice M., Nappi A., Boccaccino A., Antoniotti C., Cremolini C., Pietrantonio F., Prager G. W., Normanno N., Maiello E., Argiles G., Elez E., Signoriello G., Franco R., Falcone A., Tabernero J., Sibilia M., Ciardiello F., Martinelli E., ZITO MARINO, Federica, Cardone, Claudia, Blauensteiner, Bernadette, Moreno-Viedma, Veronica, Martini, Giulia, Simeon, Vittorio, Vitiello, Pietro P, Ciardiello, Davide, Belli, Valentina, Matrone, Nunzia, Troiani, Teresa, Morgillo, Floriana, Zito Marino, Federica, Dentice, Monica, Nappi, Annarita, Boccaccino, Alessandra, Antoniotti, Carlotta, Cremolini, Chiara, Pietrantonio, Filippo, Prager, Gerald W, Normanno, Nicola, Maiello, Evaristo, Argiles, Guillem, Elez, Elena, Signoriello, Giuseppe, Franco, Renato, Falcone, Alfredo, Tabernero, Josep, Sibilia, Maria, Ciardiello, Fortunato, Martinelli, Erika, Cardone, C., Blauensteiner, B., Moreno-Viedma, V., Martini, G., Simeon, V., Vitiello, P. P., Ciardiello, D., Belli, V., Matrone, N., Troiani, T., Morgillo, F., Zito Marino, F., Dentice, M., Nappi, A., Boccaccino, A., Antoniotti, C., Cremolini, C., Pietrantonio, F., Prager, G. W., Normanno, N., Maiello, E., Argiles, G., Elez, E., Signoriello, G., Franco, R., Falcone, A., Tabernero, J., Sibilia, M., Ciardiello, F., Martinelli, E., and ZITO MARINO, Federica

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Colorectal cancer, Population, 03 medical and health sciences, Mice, 0302 clinical medicine, Growth factor receptor, Internal medicine, Cell Line, Tumor, Proto-Oncogene Proteins, Medicine, Animals, Humans, Epithelial–mesenchymal transition, Neoplasm Metastasis, education, education.field_of_study, Cetuximab, business.industry, AXL, EGFR resistance, RAS WT, Receptor Protein-Tyrosine Kinases, Transfection, medicine.disease, Xenograft Model Antitumor Assays, Axl Receptor Tyrosine Kinase, Blockade, ErbB Receptors, 030104 developmental biology, Genes, ras, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Immunohistochemistry, business, Colorectal Neoplasms, Biomarkers, medicine.drug
Abstract

Background RAS mutations are the only validated biomarkers in metastatic colorectal cancer (mCRC) for anti-epidermal growth factor receptor (EGFR) therapy. Limited clinical information is available on AXL expression, marker of epithelial to mesenchymal transition, in mCRC. Methods AXL was retrospectively assessed by immunohistochemistry in 307 patients. RAS wild-type (WT) patients (N = 136) received first-line anti-EGFR–based therapy; RAS mutant patients (N = 171) received anti-angiogenic–based regimens. Preclinical experiments were performed using human RAS WT CRC cell lines and xenograft models. AXL RNA levels were assessed in a cohort of patients with available samples at baseline and at progression to anti-EGFR treatment and in the GSE5851 dataset. Results AXL was expressed in 55/307 tumour tissues, correlating with worse survival in the overall population (AXL-positive, 23.7 months; AXL-negative, 30.8 months; HR, 1.455, P = 0.032) and in RAS WT patients (AXL-positive, 23.0 months; AXL-negative, 35.8 months; HR,1.780, P = 0.032). Progression-free survival (PFS) in the RAS WT cohort was shorter in the AXL-positive cohort (6.2 months versus 12.1 months; HR, 1.796, P = 0.013). Three-dimensional cultures obtained from a patient following anti-EGFR therapy resulted AXL-positive, showing resistance to anti-EGFR drugs and sensitivity to AXL inhibition. AXL transfection in CRC cell lines induced AXL overexpression and resistance to the EGFR blockade. At progression to cetuximab, 2/10 SW48-tumour xenograft mice showed AXL expression. Consistently, AXL RNA levels increased in 5/7 patients following anti-EGFR therapy. Moreover, in the GSE5851 dataset higher AXL RNA levels correlated with worse PFS with cetuximab in KRAS-exon2 WT chemorefractory patients. Conclusions AXL is a marker of poor prognosis in mCRC with consistent clinical and preclinical evidences of involvement in primary and acquired resistance to anti-EGFR drugs in RAS WT patients.

Published
2020

25. 445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor

Author

Montana, F.J. Ros, primary, Martini, G., additional, Javierre, G. Villacampa, additional, Baraibar, I., additional, Comas, R., additional, Garcia, A., additional, Salva, F., additional, Gonzalez, N. Saoudi, additional, Ciardiello, D., additional, Toledo, R.D.A., additional, Martinelli, E., additional, Ciardiello, F., additional, Vivancos, A., additional, Palmer, H.G., additional, Dienstmann, R., additional, Tabernero, J., additional, and Fernandez, M.E. Elez, additional

Published
2021
Full Text
View/download PDF

26. LBA-3 Integrated analysis of cell-free DNA (cfDNA) BRAF mutant allele fraction (MAF) and whole exome sequencing in BRAFV600E metastatic colorectal cancer (mCRC) treated with BRAF-antiEGFR +/- MEK inhibitors

Author

Élez, E., primary, Ros, J., additional, Martini, G., additional, Matito, J., additional, Villacampa, G., additional, Salva, F., additional, Baraibar, I., additional, Saoudi, N., additional, Garcia, A., additional, Comas, R., additional, Ciardiello, D., additional, Martinelli, E., additional, Nuciforo, P., additional, Pálmer, H., additional, Dienstmann, R., additional, Toledo, R., additional, Ciardiello, F., additional, Tabernero, J., additional, and Vivancos, A., additional

Published
2021
Full Text
View/download PDF

27. P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy

Author

Ciardiello, D., primary, Famiglietti, V., additional, Napolitano, S., additional, Terminiello, M., additional, Borrelli, C., additional, Vitiello, P., additional, Pietrantonio, F., additional, Avallone, A., additional, Normanno, N., additional, Maiello, E., additional, Latiano, T., additional, Cremolini, C., additional, Santabarbara, G., additional, Pinto, C., additional, Santini, D., additional, Esposito, L., additional, Di Liello, A., additional, Troiani, T., additional, Ciardiello, F., additional, Martinelli, E., additional, and Martini, G., additional

Published
2021
Full Text
View/download PDF

28. 620P A phase II trial evaluating the activity of cabozantinib in pre-treated patients with metastatic colorectal cancer (mCRC): ABACO trial initial molecular data

Author

Martini, G., Troiani, T., Ciardiello, D., Napolitano, S., Famiglietti, V., Arrichiello, G., Esposito, L., Franco, R., Zito Marino, F., Panarese, I., Cardone, C., Maiello, E., Latiano, T.P., Avallone, A., Vitiello, P.P., Mariella, E., Reginelli, A., Ciardiello, F., and Martinelli, E.

Published
2023
Full Text
View/download PDF

29. 559MO Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients’ data pooled analysis from 4 phase II trials

Author

Ciardiello, D., Mauri, G., Rossini, D., Famiglietti, V., Martini, G., Napolitano, S., Del Tufo, S., Zampino, M.G., Avallone, A., Pietrantonio, F., Lonardi, S., Santini, D., Masi, G., Siena, S., Bardelli, A., Ciardiello, F., Cremolini, C., Sartore Bianchi, A., Troiani, T., and Martinelli, E.

Published
2023
Full Text
View/download PDF

31. SO-31 Comprehensive genomic profiling of tumor tissue and plasma-circulating tumor DNA in RAS/BRAFV600E wild type metastatic colorectal cancer patients: Initial findings from the CAPRI 2-GOIM trial

Author

Martini, G., Martinelli, E., Ciardiello, D., Nicastro, A., Latiano, T., Maiello, E., Avallone, A., Tamburini, E., Lonardi, S., Cremolini, C., Lolli, I., Tortora, G., Febbraro, A., Leo, S., Zampino, M., Napolitano, S., Normanno, N., Troiani, T., and Ciardiello, F.

Published
2023
Full Text
View/download PDF

32. SO-24 Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase 2 VELO trial

Author

Ciardiello, D., Napolitano, S., De Falco, V., Martini, G., Martinelli, E., Della Corte, C., Esposito, L., Famiglietti, V., Di Liello, A., Avallone, A., Cardone, C., De Stefano, A., Montesarchio, V., Zampino, M., Fazio, N., Del Tufo, S., Di Maio, M., De Vita, F., Altucci, L., Marrone, F., Ciardiello, F., and Troiani, T.

Published
2023
Full Text
View/download PDF

35. 13P Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status

Author

Giunta, E.F., primary, Belli, V., additional, Napolitano, S., additional, De Falco, V., additional, Vitiello, P.P., additional, Terminiello, M., additional, Caputo, V., additional, Vitale, P., additional, Zanaletti, N., additional, Ciardiello, D., additional, Argenziano, G., additional, Martinelli, E., additional, Martini, G., additional, and Troiani, T., additional

Published
2020
Full Text
View/download PDF

36. 397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study

Author

Martinelli, E., primary, Martini, G., additional, Troiani, T., additional, Pietrantonio, F., additional, Avallone, A., additional, Normanno, N., additional, Nappi, A., additional, Maiello, E., additional, Falcone, A., additional, Santabarbara, G., additional, Pinto, C., additional, Santini, D., additional, Ciardiello, D., additional, Terminiello, M., additional, Borrelli, C., additional, Napolitano, S., additional, Renato, D., additional, Famiglietti, V., additional, Esposito, L., additional, and Ciardiello, F., additional

Published
2020
Full Text
View/download PDF

37. 487P Use of patient-derived tumour organoids to identify acquired treatment resistance and determine optimal post-progression combinations in metastatic colorectal cancer

Author

Martini, G., primary, Borreil, I. Puig, additional, Ramirez, L., additional, Chicote, I., additional, Mancuso, F.M., additional, Caratu, G., additional, Serres-Créixams, X., additional, Fasani, R., additional, Jimenez, J., additional, Montañá, F.J. Ros, additional, Argota, I. Baraibar, additional, Ciardiello, D., additional, Margalef, N. Mulet, additional, Dienstmann, R., additional, Vivancos, A., additional, Elez, E., additional, Palmer, H., additional, Tabernero, J., additional, and Martinez, G. Argiles, additional

Published
2020
Full Text
View/download PDF

38. 1951P Niraparib and irinotecan combination in ATM-mutated colorectal cancer

Author

Vitiello, P.P., primary, Martini, G., additional, Mele, L., additional, Giunta, E.F., additional, De Falco, V., additional, Ciardiello, D., additional, Belli, V., additional, Cardone, C., additional, Matrone, N., additional, Poliero, L., additional, Tirino, V., additional, Selvaggi, F., additional, Papaccio, G., additional, Troiani, T., additional, Desiderio, V., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2020
Full Text
View/download PDF

39. 499P Heterogeneity in the immune inflamed biomarkers of MSS and MSI colorectal cancer

Author

Argota, I. Baraibar, primary, Rubio-Pérez, C., additional, Martinez, G. Argiles, additional, Montañá, F.J. Ros, additional, Salvà, F., additional, Margalef, N. Mulet, additional, Urteaga, J.L. Cuadra, additional, Castaneda, D.H. Marmolejo, additional, Gonzalez, N. Saoudi, additional, Ciardiello, D., additional, Tabernero, J., additional, Seoane, J., additional, and Elez, E., additional

Published
2020
Full Text
View/download PDF

40. 461P Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience

Author

Vitiello, P.P., primary, De Falco, V., additional, Giunta, E.F., additional, Ciardiello, D., additional, Canciello, M.A., additional, Cardone, C., additional, Vitale, P., additional, Zanaletti, N., additional, Borrelli, C., additional, Poliero, L., additional, Terminiello, M., additional, Arrichiello, G., additional, Caputo, V., additional, Martini, G., additional, Napolitano, S., additional, Lombardi, A., additional, Caraglia, M., additional, Troiani, T., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2020
Full Text
View/download PDF

41. P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution

Author

Giunta, E., primary, De Falco, V., additional, Napolitano, S., additional, Vitale, P., additional, Zanaletti, N., additional, Terminiello, M., additional, Caputo, V., additional, Vitiello, P., additional, Ciardiello, D., additional, Borrelli, C., additional, Poliero, L., additional, Arrichiello, G., additional, Cardone, C., additional, Martini, G., additional, Martinelli, E., additional, Ciardiello, F., additional, and Troiani, T., additional

Published
2020
Full Text
View/download PDF

42. O-21 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites

Author

Kagawa, Y., primary, Fernandez, E. Elez, additional, Garcia-Foncillas, J., additional, Bando, H., additional, Taniguchi, H., additional, Vivancos, A., additional, Akagi, K., additional, Garcia, A., additional, Denda, T., additional, Ros, J., additional, Nishina, T., additional, Baraibar, I., additional, Komatsu, Y., additional, Ciardiello, D., additional, Oki, E., additional, Satoh, T., additional, Kato, T., additional, Yamanaka, T., additional, Tabernero, J., additional, and Yoshino, T., additional

Published
2020
Full Text
View/download PDF

43. P-190 A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data

Author

Vitale, P., primary, Zanaletti, N., additional, Lombardi, P., additional, Milanesio, M., additional, Falco, V. De, additional, Terminiello, M., additional, Giunta, E., additional, Vitiello, P., additional, Caputo, V., additional, Borrelli, C., additional, Arrichiello, G., additional, Poliero, L., additional, Ciardiello, D., additional, Napolitano, S., additional, Martini, G., additional, Martinelli, E., additional, Famiglietti, V., additional, Fenocchio, E., additional, Keränen, S. Roselló, additional, Cervantes, A., additional, Ciardiello, F., additional, and Troiani, T., additional

Published
2020
Full Text
View/download PDF

44. Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer

Author

Ciardiello, D., primary, Belli, V., additional, Cardone, C., additional, Vitiello, P.P., additional, Martini, G., additional, Poliero, L., additional, Borrelli, C., additional, Arrichiello, G., additional, Ciaramella, V., additional, Matrone, N., additional, Barra, G., additional, De Falco, V., additional, Giunta, E.F., additional, Morgillo, F., additional, Troiani, T., additional, Terminiello, M., additional, Melisi, D., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2019
Full Text
View/download PDF

45. GLPG 1790, a new selective EPHA2 inhibitor, is active in colorectal cancer cell lines belonging to the CMS4/mesenchymal-like subtype

Author

Vitiello, P.P., primary, Mele, L., additional, Prisco, C., additional, Cardone, C., additional, Ciardiello, D., additional, Poliero, L., additional, Borrelli, C., additional, Zanaletti, N., additional, Vitale, P., additional, Tirino, V., additional, Papaccio, G., additional, Troiani, T., additional, Ciardiello, F., additional, Marampon, F., additional, Desiderio, V., additional, and Martinelli, E., additional

Published
2019
Full Text
View/download PDF

46. IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients

Author

Giunta, E.F., primary, Barra, G., additional, De Falco, V., additional, Vitale, P., additional, Zanaletti, N., additional, Terminiello, M., additional, Caputo, V., additional, Napolitano, S., additional, Vitiello, P.P., additional, Ciardiello, D., additional, Belli, V., additional, Brancaccio, G., additional, Argenziano, G., additional, De Palma, R., additional, Ciardiello, F., additional, and Troiani, T., additional

Published
2019
Full Text
View/download PDF

47. Synergistic activity between niraparib and chemotherapy in colorectal cancer: Molecular determinants from a preclinical model

Author

Vitiello, P.P., primary, Ciardiello, D., additional, Cardone, C., additional, Martini, G., additional, Belli, V., additional, Borrelli, C., additional, Poliero, L., additional, Arrichiello, G., additional, De Falco, V., additional, Giunta, E.F., additional, Terminiello, M., additional, Troiani, T., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2019
Full Text
View/download PDF

48. AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)

Author

Cardone, C., primary, Blauensteiner, B., additional, Moreno-Viedma, V., additional, Vitiello, P.P., additional, Martini, G., additional, Ciardiello, D., additional, Simeon, V., additional, Rachiglio, A.M., additional, Rizzi, D., additional, Maiello, E., additional, Latiano, T., additional, Cremolini, C., additional, Argiles Martinez, G., additional, Elez, E., additional, Falcone, A., additional, Tabernero, J., additional, Normanno, N., additional, Sibilia, M., additional, Ciardiello, F., additional, and Martinelli, E., additional

Published
2019
Full Text
View/download PDF

49. Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells

Author

Matrone, N., primary, Napolitano, S., additional, Belli, V., additional, Barra, G., additional, Giunta, E.F., additional, De Falco, V., additional, Terminiello, M., additional, Vitiello, P.P., additional, Ciardiello, D., additional, Turano, M., additional, Furia, M., additional, Muddassir, A.S., additional, Kopetz, S., additional, Martinelli, E., additional, Ciardiello, F., additional, and Troiani, T., additional

Published
2019
Full Text
View/download PDF

50. Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

Author

De Falco, V., primary, Vitiello, P., additional, Giunta, E., additional, Ciardiello, D., additional, Stefania, N., additional, Cardone, C., additional, Vitale, P., additional, Zanaletti, N., additional, Terminiello, M., additional, Poliero, L., additional, Borrelli, C., additional, Caputo, V., additional, Arrichiello, G., additional, Mattera Iacono, V., additional, Marrone, F., additional, Famiglietti, V., additional, Martinelli, E., additional, Ciardiello, F., additional, and Troiani, T., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results